Target- |
Mechanism- |
|
|
|
Inactive Indication- |
Drug Highest PhasePhase 1 |
First Approval Ctry. / Loc.- |
First Approval Date- |
|
|
|
|
|
Inactive Indication- |
Drug Highest PhasePhase 1 |
First Approval Ctry. / Loc.- |
First Approval Date- |
靶向Mesothelin CAR-NK 细胞注射液治疗晚期上皮性卵巢癌的 I 期临床研究
[Translation] Phase I clinical study of targeted mesothelin CAR-NK cell injection in the treatment of advanced epithelial ovarian cancer
Ia期阶段主要目的是评价靶向Mesothelin CAR-NK细胞注射液单次给药治疗晚期上皮性卵巢癌患者的安全性、耐受性、疗效、药代动力学/药效动力学,
Ib期阶段主要目的是评价靶向Mesothelin CAR-NK细胞注射液多次给药治疗晚期上皮性卵巢癌患者的安全性及耐受性,确定II期临床研究推荐剂量(RP2D)、疗效、药代动力学/药效动力学。
[Translation] The main purpose of the Phase Ia phase is to evaluate the safety, tolerability, efficacy, and pharmacokinetics/pharmacodynamics of a single dose of targeted Mesothelin CAR-NK cell injection in the treatment of patients with advanced epithelial ovarian cancer. The main purpose of the Phase Ib phase is to evaluate the safety and tolerability of multiple doses of targeted Mesothelin CAR-NK cell injection in the treatment of patients with advanced epithelial ovarian cancer and to determine the recommended dose (RP2D), efficacy, and pharmacokinetics/pharmacodynamics for Phase II clinical studies.
100 Clinical Results associated with Guojian Chengnuo Biotechnology (Beijing) Co., Ltd
0 Patents (Medical) associated with Guojian Chengnuo Biotechnology (Beijing) Co., Ltd
100 Deals associated with Guojian Chengnuo Biotechnology (Beijing) Co., Ltd
100 Translational Medicine associated with Guojian Chengnuo Biotechnology (Beijing) Co., Ltd